Kymera Therapeutics (KYMR) Cash from Financing Activities (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Cash from Financing Activities data on file, last reported at $18.8 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $18.8 million, up 7174.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 295.23% YoY), and the FY2025 annual result was $990.7 million, up 62.72% from the prior year.
• Cash from Financing Activities declined to $18.8 million in Q1 2026 per KYMR's latest filing, from $705.2 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $705.2 million in Q4 2025 and troughed at -$206000.0 in Q3 2023.
• A 5-year average of $104.4 million and a median of $2.0 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities sank 100.14% in 2023, then jumped 121904.85% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $2.0 million in 2022, then decreased by 0.97% to $1.9 million in 2023, then surged by 42.97% to $2.8 million in 2024, then surged by 25405.21% to $705.2 million in 2025, then plunged by 97.34% to $18.8 million in 2026.
• Business Quant data shows KYMR's Cash from Financing Activities at $18.8 million in Q1 2026, $705.2 million in Q4 2025, and $39.5 million in Q3 2025.